Ocera Therapeutics (OCRX) Reports Q1 Loss Per Share of $0.28, Offers Guidance
Get Alerts OCRX Hot Sheet
Join SI Premium – FREE
Ocera Therapeutics (NASDAQ: OCRX) reported Q1 EPS of ($0.28), versus ($0.36) reported last year.
Financial Guidance
Ocera expects net use of cash for 2017 to be in the range of $24.0 million to $27.0 million, including $3.1 million in scheduled principal repayments on notes payable, and reiterates its previous guidance that it will have sufficient cash to fund operations into the second quarter of 2018 based on its current operating plan.
For earnings history and earnings-related data on Ocera Therapeutics (OCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
- Fifth Third Bancorp (FITB) Tops Q1 EPS by 2c
- Lakeland Bancorp (LBAI) Tops Q1 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!